131 results match your criteria: "Centre de Reference des Maladies Pulmonaires Rares[Affiliation]"

ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly.

ERJ Open Res

April 2022

Center for Interstitial Lung Diseases and Sarcoidosis, Dept of Respiratory Medicine, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands.

Article Synopsis
  • - The article reviews key scientific advancements in interstitial lung disease (ILD) presented at the 2021 European Respiratory Society Congress, which was conducted virtually.
  • - Topics covered include translational and genetic research, as well as new innovations aimed at enhancing patient care.
  • - Early Career Members summarize noteworthy findings from various congress sessions, in collaboration with the leadership of Assembly 12 which focuses on ILD.
View Article and Find Full Text PDF

[Respiratory physiotherapy in 2022: A multimodal approach].

Rev Mal Respir

April 2022

Service de pneumologie et soins intensifs respiratoires, centre de référence des maladies pulmonaires rares de l'adulte, CHU de Dijon-Bourgogne, Dijon, France; Université de Bourgogne Franche-Comté, Dijon, France; UMR 6265 CNRS 1234 INRA, centre des sciences du goût et de l'alimentation, université de Bourgogne Franche-Comté, Dijon, France. Electronic address:

View Article and Find Full Text PDF

FGF19 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice.

Am J Respir Cell Mol Biol

August 2022

Faculté de Médecine Xavier Bichat, Université de Paris, Institut National de la Santé et de la Recherche Médicale (INSERM), UMR1152, FHU APOLLO, Labex INFLAMEX, Paris, France.

Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease with limited therapeutic possibilities. FGF19 (fibroblast growth factor 19), an endocrine FGF, was recently shown to decrease liver fibrosis. To ask whether FGF19 had antifibrotic properties in the lung and decipher its effects on common features associated with lung fibrogenesis, we assessed, by ELISA, FGF19 concentrations in plasma and BAL fluids obtained from control subjects and patients with IPF.

View Article and Find Full Text PDF

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with pulmonary endothelial dysfunction. There are limited data available on the outcomes of coronavirus disease (COVID-19) in patients with pulmonary hypertension (PH), a disease characterized by pulmonary endothelial dysfunction. To describe characteristics and outcomes of patients with precapillary PH and COVID-19.

View Article and Find Full Text PDF

Comorbidities of sarcoidosis.

Ann Med

December 2022

Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy.

Sarcoidosis is a heterogeneous disease, which can affect virtually every body organ, even though lungs and intra thoracic lymph nodes are almost universally affected. The presence of noncaseating granulomas is the histopathological hallmark of the disease, and clinical picture depends on the organs affected. Data about interaction between sarcoidosis and comorbidities, such as cardiovascular and pulmonary diseases, autoimmune disorders, malignancy and drug-related adverse events are limited.

View Article and Find Full Text PDF

Idiopathic pulmonary fibrosis (IPF) is associated with several hallmarks of aging including telomere shortening, which can result from germline mutations in telomere related genes (TRGs). Here, we assessed the length and stability of telomeres as well as the integrity of chromosomes in primary lung fibroblasts from 13 IPF patients (including seven patients with pathogenic variants in TRGs) and seven controls. Automatized high-throughput detection of telomeric FISH signals highlighted lower signal intensity in lung fibroblasts from IPF patients, suggesting a telomere length defect in these cells.

View Article and Find Full Text PDF

[Systemic sclerosis-related interstitial lung disease: Diagnostic and therapeutic strategy in the light of recent clinical trials].

Rev Med Interne

June 2022

Inserm, service de médecine interne et immunologie clinique, U1286, INFINITE, Institute for Translational Research in Inflammation, centre de référence des maladies autoimmunes systémiques rares du Nord et Nord-Ouest de France (CeRAINO), University Lille, CHU de Lille, 59000 Lille, France.

Systemic sclerosis (SSc) is an autoimmune disease associated to fibrotic manifestations. Interstitial lung disease (SSc-ILD), one of the main fibrotic features of SSc, is the first cause of SSc-related death. The management of SSc-ILD has recently benefited from the results of key randomised controlled trials.

View Article and Find Full Text PDF

Patients diagnosed with coronavirus disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection frequently experience symptom burden post-acute infection or post-hospitalisation. We aimed to identify optimal strategies for follow-up care that may positively impact the patient's quality of life (QoL). A European Respiratory Society (ERS) Task Force convened and prioritised eight clinical questions.

View Article and Find Full Text PDF

Sarcoidosis-associated pulmonary hypertension (SAPH) is an important complication of advanced sarcoidosis. Over the past few years, there have been several studies dealing with screening, diagnosis and treatment of SAPH. This includes the results of two large SAPH-specific registries.

View Article and Find Full Text PDF

Background: Monogenic and polygenic inheritances are evidenced for idiopathic pulmonary fibrosis (IPF). Pathogenic variations in surfactant protein-related genes, telomere-related genes (TRGs), and a single-nucleotide polymorphism in the promoter of MUC5B gene encoding mucin 5B (rs35705950 T risk allele) are reported. This French-Greek collaborative study, Gen-Phen-Re-GreekS in inheritable IPF (iIPF), aimed to investigate genetic components and patients' characteristics in the Greek national IPF cohort with suspected heritability.

View Article and Find Full Text PDF

Introduction: Patients with short telomere-related interstitial lung disease (ILD) have worse outcomes after lung transplantation. We hypothesized that post-transplant airway complications, including dehiscence and bronchial stenosis, would be more common in the short telomere ILD lung transplant population.

Methods: We conducted a multi-institutional (Brigham and Women's Hospital, Groupe de Transplantation de la SPLF) retrospective cohort study of 63 recipients between 2009 and 2019 with ILD and short telomeres, compared to 4359 recipients from the Scientific Registry of Transplant Recipients with ILD and no known telomeropathy.

View Article and Find Full Text PDF

Carriers of germline telomerase-related gene (TRG) mutations can show poor prognosis, with an increase in common hematological complications after lung transplantation (LT) for pulmonary fibrosis. The aim of this study was to describe the outcomes after LT in recipients carrying a germline TRG mutation and to identify the predictors of survival. In a multicenter cohort of LT patients, we retrospectively reviewed those carrying pathogenic TRG variations (n = 38; TERT, n = 23, TERC, n = 9, RTEL1, n = 6) between 2009 and 2018.

View Article and Find Full Text PDF

Background: There is growing evidence of gender-specific phenotypic differences among patients with idiopathic pulmonary fibrosis (IPF), which may affect patient outcomes.

Objectives: We present the characteristics of patients with IPF at inclusion in the French Rare Disease Cohort - Interstitial Lung Disease (RaDiCo-ILD) with the aim of characterizing gender-specific phenotypic differences.

Methods: Patients with IPF who were enrolled in the national, multicentre RaDiCo-ILD cohort were included.

View Article and Find Full Text PDF

Blood fibrocytes are associated with severity and prognosis in COVID-19 pneumonia.

Am J Physiol Lung Cell Mol Physiol

November 2021

Laboratoire d'excellence INFLAMEX, Université de Paris, Inserm, U1152, Paris, France.

Increased blood fibrocytes are associated with a poor prognosis in fibrotic lung diseases. We aimed to determine whether the percentage of circulating fibrocytes could be predictive of severity and prognosis during coronavirus disease 2019 (COVID-19) pneumonia. Blood fibrocytes were quantified by flow cytometry as CD45/CD15/CD34/collagen-1 cells in patients hospitalized for COVID-19 pneumonia.

View Article and Find Full Text PDF

Clinical Impact of Surgical Lung Biopsy for Interstitial Lung Disease in a Reference Center.

Ann Thorac Surg

September 2022

Service de Chirurgie vasculaire, thoracique, et transplantation pulmonaire, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France; Labex INFLAMEX, INSERM U1152, Faculté Bichat, Université de Paris, Paris, France. Electronic address:

Background: Diagnosis of interstitial lung disease is based on the analysis of clinical, biological, radiological, and pathological findings during a multidisciplinary discussion (MDD). When a definitive diagnosis is not possible, guidelines recommend obtaining lung samples through surgical lung biopsy (SLB). We sought to determine morbidity, mortality, diagnostic yield, and therapeutic impact of SLB in the management of patients with interstitial lung disease.

View Article and Find Full Text PDF

Air pollution and poverty: a deadly combination in idiopathic pulmonary fibrosis?

Eur Respir J

October 2021

Centre de référence des maladies pulmonaires rares (site constitutif), AP-HP, Service de Pneumologie, Hôpital Avicenne - Université Sorbonne Paris Nord, INSERM 1272, «Hypoxie et Poumon: pneumopathies fibrosantes, modulations ventilatoires et circulatoires», Bobigny, France.

View Article and Find Full Text PDF

Drug-induced sarcoidosis-like reactions.

Curr Opin Pulm Med

September 2021

Hôpital Avicenne, Service de Pneumologie, Centre de Référence des Maladies Pulmonaires Rares de l'adulte, Bobigny, France.

Purpose Of Review: Sarcoidosis is a complex granulomatous disease of unknown cause. Several drug categories are able to induce a systemic granulomatous indistinguishable from sarcoidosis, known as drug-induced sarcoidosis-like reaction (DISR). This granulomatous inflammation can resolve if the medication is discontinued.

View Article and Find Full Text PDF

Background: The major reasons to treat sarcoidosis are to lower the morbidity and mortality risk or to improve quality of life (QoL). The indication for treatment varies depending on which manifestation is the cause of symptoms: lungs, heart, brain, skin or other manifestations. While glucocorticoids remain the first choice for initial treatment of symptomatic disease, prolonged use is associated with significant toxicity.

View Article and Find Full Text PDF

Low income and outcome in idiopathic pulmonary fibrosis: An association to uncover.

Respir Med

July 2021

Centre de Référence des Maladies Pulmonaires Rares (site Constitutif), AP-HP, Service de Pneumologie, Hôpital Avicenne, Bobigny, France; Université Sorbonne Paris Nord, INSERM, 1272, « Hypoxie et Poumon: Pneumopathies Fibrosantes, Modulations Ventilatoires et Circulatoires », Bobigny, France. Electronic address:

Article Synopsis
  • - The study investigates the impact of low income on patients with idiopathic pulmonary fibrosis (IPF), a chronic respiratory disease, hypothesizing that lower income worsens patient prognosis.
  • - Researchers analyzed data from the French COFI cohort, categorizing patients into "low income" and "higher income" groups based on their annual income, and compared survival rates using statistical models.
  • - Results showed that low-income patients had significantly worse progression-free survival and overall survival rates, alongside a higher likelihood of having non-European origin and occupational exposures, underscoring the adverse effects of low income on IPF outcomes.
View Article and Find Full Text PDF

Lysosomes are intracellular organelles that are responsible for degrading and recycling macromolecules. Lysosomal storage diseases (LSDs) are a group of inherited diseases caused by mutations affecting genes that encode the function of the lysosomal enzymes. Three LSDs are associated with lung involvement and/or interstitial lung disease (ILD): Gaucher disease (GD); Niemann-Pick disease, also known as acid sphingomyelinase deficiency (ASMD); and Fabry disease (FD).

View Article and Find Full Text PDF

[COVID-19, severe asthma, and biologic].

Rev Mal Respir

April 2021

Unité de Recherche Clinique, Centre Hospitalier Henri Laborit, Université de Poitiers, 370, avenue Jacques Cœur, CS 10587, 86021 Poitiers, France.

View Article and Find Full Text PDF

No evidence for a pathogen associated with pulmonary MALT lymphoma: a metagenomics investigation.

Infect Agent Cancer

February 2021

Service de Pneumologie et Oncologie thoracique, Centre de référence des maladies pulmonaires rares, AP-HP, Hôpital Tenon and GRC#4 Theranoscan, Sorbonne Université, Paris, France.

Mucosa-associated lymphoid tissue (MALT) lymphoma is generally associated with chronic antigen stimulation: auto-antigens or of microbial origin. Only one study suggested association between Achromobacter xylosoxidans and pulmonary MALT lymphoma. We aimed to investigate the presence of virus or any infectious agents in pulmonary MALT lymphoma by using metagenomic next-generation sequencing (mNGS).

View Article and Find Full Text PDF

Background: Severe asthma is a chronic lung disease characterised by inflammation, airway hyperresponsiveness (AHR) and airway remodelling. The molecular mechanisms underlying uncontrolled airway smooth muscle cell (aSMC) proliferation involved in pulmonary remodelling are still largely unknown. Small G proteins of the Rho family (RhoA, Rac1 and Cdc42) are key regulators of smooth muscle functions and we recently demonstrated that Rac1 is activated in aSMC from allergic mice.

View Article and Find Full Text PDF

The French-speaking Respiratory Medicine Society (SPLF) proposes a guide for the management of possible respiratory sequelae in patients who have presented with SARS-CoV-2 pneumonia (COVID-19). The proposals are based on known data from previous epidemics, preliminary published data on post COVID-19 follow-up and on expert opinion. The proposals were developed by a group of experts and then submitted, using the Delphi method, to a panel of 22 pulmonologists.

View Article and Find Full Text PDF